The behavior of dispersible tablets containing enteric-coated pellets and oral suspension, both containing roxithromycin, was investigated using dissolution tests in different media. The dissolution test was performed under different pH conditions. For both dosage forms investigated, the test was conducted at pH 1.2, 4.5, and 6.8. Additionally, for dispersible tablets, the test involving increasing pH was performed at pH 1.2 (acid stage) and afterwards at pH 6.8 (buffer stage). The extent of dissolution was measured using high-performance liquid chromatography (HPLC). In all cases tested, roxithromycin underwent rapid degradation at pH 1.2. Dispersible tablets displayed the features of modified release preparations with a non-complete dissolution during the test times in all media. Conversely, the oral suspension behaved as an immediate release preparation, with degradation at pH 1.2. However, the dissolution of the oral suspension at pH 4.5 and 6.8 was rapid and complete. The role of enteric-coated pellets is to mask the bitter taste of the active substance upon administration. However, the coating showed lack of resistance to media at pH 1.2. Therefore, dispersible tablets containing enteric-coated pellets are not pharmaceutically equivalent to the immediate-release oral suspension.
Introduction

Roxithromycin ((E)-erythromycin-9-[O-[(2-methoxyethoxy)-methyl]oxime]) is a semi-synthetic macrolide antibiotic derivative of erythromycin A (Figure 1a
. It shows an in vitro spectrum of antimicrobial activity similar to the parent compound, but has greater potency and longer action. Roxithromycin has fewer undesired interactions than erythromycin because it has a lower affinity for cytochrome P450. It is used to treat infections of the respiratory tract, genitourinary tract, skin, and soft tissues, as well as to treat orodental infections [1] [2] [3] . Its safety and effectiveness account for frequent use in the treatment of pediatric infections. The mechanism of its bacteriostatic action, as with other macrolide antibiotics, is thought to involve inhibition of RNA-dependent bacterial protein synthesis [4, 5] . Roxithromycin has a 14-membered macrolide nucleus with two carbohydrates: neutral cladinose and aminosugar desosamine ( Figure 1b) . It shows better stability under acidic conditions than that of erythromycin related to the presence of the oxime ether side chain at position 9, which prevents internal enolic ether formation [6] . For that reason, it is usually not protected with coatings resistant to gastric juice in pharmaceutical dosage forms. Nevertheless, partial lost of antibacterial activity is observed in a strongly acidic environment. This is caused by detachment of the cladinose sugar moiety, which leads to the formation of the essentially non-active decladinose roxithromycin (Figure 1c ) [7, 8] .
Most commercially available pharmaceutical dosage forms of roxithromycin are non-modified release preparations. Only a pediatric dosage form exists on a market as modified release tablets for oral suspension; this form disintegrates into pellets coated with copolymers of methacrylic acid ethylic ether soluble above pH 5.5. However, the function of this coating is not protection from the acidic conditions of stomach, but to mask the bitter taste of the active ingredients. These tablets also contain fumaric acid, which keeps the pH of suspension below 5.5 and protects the pellets from roxithromycin dissolution in an aqueous environment, both before administration to the patient and in the oral cavity, where pH of saliva is above 5.5. That, in turn, improves acceptance of the preparation among pediatric patients. Despite that, in some countries a pediatric dosage form exists as a non-modified release oral suspension where crystals of roxithromycin are suspended directly in an aqueous environment. That form has a bitter taste, decreasing its acceptance by children. According to results presented in one recent study [9] concerning roxithromycin in vivo stability, it is probable that the suspension containing enteric-coated pellets prepared from dispersible tablets could display different behavior during a dissolution test than that of the non-modified release oral suspension. The possible consequences include differences in pharmacokinetics and in clinical response resulting from the lack of antibacterial activity of the main acid degradation product, decladinose roxithromycin. The pharmacokinetics and bioavailability of roxithromycin from the enteric-coated pellets and the non-modified release suspension prepared from dispersible tablets (that did not contain enteric-coated pellets) were also compared in that study by Sun et al. Their results showed that roxithromycin in the form of enteric-coated pellets demonstrated better stability in vivo and better bioavailability than that of the nonmodified release oral suspension.
Our recent work revealed the possibility of establishing reliable in vivo and in vitro correlation for the immediate release form of beta-lactam class antibiotic amoxicillin [10] . The aim of the current work was focused on another antibiotic class, namely, macrolides. The goal was to characterize roxithromycin dissolution from commercially available tablets in the cases of an oral suspension containing pellets coated with copolymers of methacrylic acid ethylic ether soluble above pH 5.5 (modified release form) and in suspension (immediate release form) prepared from powder that had been suspended in a specified amount of water. Subsequently, the results from in vitro test were used to estimate the extent of possible agreement with the results presented in the Sun et al. study, as well as to predict and reveal the biopharmaceutical properties of both the pharmaceutical dosage forms tested.
Material and Methods
Materials
Commercially available tablets for oral suspension Rulid ® 50 mg (Aventis, Paris, France), (batch 7CM5H) were used. The model powder for oral suspension (batch 10906) was provided by Polfa Tarchomin S.A. (Warszawa, Poland). After adding the prescribed amount of water (5 mL) the powder formed a suspension containing 50 mg of roxithromycin. The powder for oral suspension consisted of standard ingredients for this 
Dissolution testing
All dissolution tests were performed using the Hanson SR8 Plus apparatus (Hanson Research, Chatsworth, CA, USA). Twelve dosage units were tested in each experiment.
Tests in a buffer (pH 1.2) were performed using USP and EP apparatus type 2 (paddles) with 1000 mL of medium at a rotation speed of 75 rpm. The pH Tests in a pH 4.5 buffer were performed using USP and EP apparatus type 2 (paddles) with 1000 mL of medium at a rotation speed of 75 rpm. The pH 4.5 buffer was prepared according to EP 5.7 by dissolving 2.99 g of sodium acetate in water, adding 14 mL 2 M acetic acid and diluting the solution to 1000 mL with deionized water. Samples of 10 mL were withdrawn from each dissolution vessel at 15, 30, and 45 min of the test and filtered through 1 µm filter prior to analysis.
Tests in a pH 6.8 buffer were performed using USP and EP apparatus type 2 (paddles) with 1000 mL of medium at a rotation speed of 75 rpm. The pH 6.8 buffer was prepared according to EP 5.7 by mixing 0.2 M solution of potassium dihydrogen phosphate, 0.2 M solution of sodium hydroxide, and deionized water (250:112:638 v/v/v). Samples of 10 mL were withdrawn from each dissolution vessel at 15, 30, and 45 min of the test and filtered through 1 µm filter prior to analysis
Tests under increasing pH, from 1.2 to 6.8, were performed using USP and EP apparatus type 2 (paddles) according to the modified prescription of EP 5.7. In the acid stage, 750 mL buffer at pH 1.2 prepared with the previously mentioned prescription of EP 5.7 was used. A 10 mL sample was withdrawn at 60 min and filtered through 1 µm filter prior to analysis. Subsequently, at 60 min, 250 mL of an 0.2 M solution of Na 3 PO 4 and 1 mL of 2 M HCl (to adjust the pH to 6.8) were added (buffer stage) at a rotation speed of 75 rpm. Samples of 10 mL were withdrawn from each dissolution vessel at 75, 90, and 105 min of the test and filtered through 1 µm filter prior to analysis.
All reagents were of analytical purity. 
HPLC analysis
Results
The tested pharmaceutical dosage forms demonstrated different dissolution behavior. The dispersible tablets had features of the modified release product, which was confirmed by incomplete dissolution of an active substance in buffer at pH 6.8 during 45 min of the test (Table 1) . At pH 4.5, the dissolution was also limited and also decreased through resistance of the pellets to a pH 4.5 buffer. At pH 1.2 roxithromycin was liberated from the pellets, but degraded rapidly because of its acid instability. The dissolution profile of the degradation product was similar to the dissolution profile of roxithromycin at pH 6.8 ( Figure 3) . The calculated similarity factor, f 2 , was 56.67. The results confirmed that the coating provides only taste-masking when the drug is administered to a patient. The coating is not resistant to an aggressive pH 1.2 medium. The study of dispersible tablets involving increasing pH (started from acid stage at pH 1.2 followed by buffer stage at pH 6.8) provided also similar results, demonstrating liberation and fast degradation of roxithromycin during acid stage at pH 1.2 (Table 2) . During the pH 6.8 buffer stage, the remainder of the active substance was liberated from the pellets. The dispersible tablets are not at the enteric dosage form as a result of the dissolution during an acid stage higher than 10% (Figure 4) . The purpose of acid-buffer stage experiment was to simulate the passage of entericcoated pellets through the GI tract. Such methodology is also described and required by pharmacopeia for enteric- a b coated dosage forms. These results can be considered reasonable because an acid-buffer stage experiment seems to be a better way to simulate physiological conditions. Therefore, it clearly shows that the entericcoated pellets tested in the present study under acidic conditions partially liberate roxithromycin, which subsequently undergoes degradation and thus reduces the effective dosage. The drug that is liberated at pH 6.8 is not at the same dosage as the original. Moreover, it shows that enteric-coated pellets provide better (but not complete) protection than the conventional immediaterelease dosage form. Table 2 . Dissolution of roxithromycin and its degradation product from tablets for oral suspension at pH 1.2-6.8 (acid stage-buffer stage).
The suspension prepared from the powder showed all the features of the immediate and non-modified release product (Table 3) . At pH 1.2, full degradation of roxithromycin occurred. After 15 min of the test at pH 1.2, only a small amount of roxithromycin remained in solution. At pH 4.5 and 6.8 after 15 min of the test, dissolution of roxithromycin was complete ( Figure 5 ).
Discussion
The research demonstrated different dissolution behavior of both pharmaceutical dosage forms tested, which confirms and justifies the results of roxithromycin bioavailability presented by Sun et al. Its sensitivity to a strongly acidic environment may cause partial degradation in vivo. The bioavailability study described in the previous study was performed with adult volunteers, where the expected pH in stomach is lower than in the pediatric population. Important factors influencing pH-dependent roxithromycin bioavailability Table 3 . Dissolution of roxithromycin and its degradation product from suspension at pH 1.2, 4.5, and 6.8. also include individual differences in the pH of gastric juice among subjects. The variability of the area under the curve (AUC) at 42.70 (±16.28) mg·h/L for the nonmodified release dosage form may be connected with different rates of degradation depending on the pH of gastric juice and stomach emptying time [9] . On the other hand, variability of AUC at 60.85 (±11.23) mg·h/L was lower in the case of pellets. Results presented in another study [11] indicated that in the pH range 1.0 to 1.8, the rate of roxithromycin degradation changes rapidly. The half-life at pH 1.0 was 6.5 min, at pH 1.3 was 17 min, and at pH 1.8 was 51 min, confirming that relatively small variations in the pH of gastric juice may have an important influence on in vivo degradation and bioavailability. Moreover, roxithromycin should be administered before meals when the gastric juice has a lower pH, which might be another factor influencing its stability. On the other hand, gastric pH is higher in the pediatric population, especially in infants and younger children, which can be assumed to be a physiological state. In turn, it may have a positive impact on the gastric stability and pharmacokinetics of an active substance. Different in vivo and in vitro behaviors of the roxithromycin pharmaceutical dosage forms studied originate not only from gastric stability issues. It appears that important factors include also a delayed release of the antibiotic from enteric-coated pellets, which Sun et al. also discussed: the T max for enteric coated pellets was 2.83 (±0.99) h, and for non-modified release form it was 1.42 (±0.84) h).
For the reasons we have presented here, it can be concluded that pharmaceutical dosage forms containing enteric-coated pellets of roxithromycin should not be replaced in clinical practice with the non-modified release dosage forms, such as bioequivalent suspensions and tablets [12] .
Those considerations can also be applied to the very similar situation in another macrolide antibiotic, namely, clarithromycin. It is also sensitive to strongly acidic conditions; it degrades to non-active decladinose clarithromycin [13, 14] . In addition to prolonged-release tablets, clarithromycin is commercially available in the form of a suspension containing enteric-coated pellets that are soluble above pH 5.5, and also as non-modified release coated tablets. roxithromycin pH 1.2 degradation product pH 1.2 roxithromycin pH 4.5 roxithromycin pH 6.8 Figure 5 . Dissolution of roxithromycin and its degradation product from suspension at pH 1.2, 4.5, and 6.8.
